IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses

IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA)

Breast to lung cancers: IDEAYA puts IDE574 into human testing